Seeking Alpha

AstraZeneca (AZN +0.2%) says an Appeals Court has upheld the decision finding that the substance...

AstraZeneca (AZN +0.2%) says an Appeals Court has upheld the decision finding that the substance patent protecting Crestor is valid and enforceable. The defendants may seek a rehearing or review by the U.S. Supreme Court. Absent a reversal, none of the Abbreviated New Drug Applications filed may be approved by the FDA prior to expiration of the patent, which expires in 2016. The ruling covers rosuvastatin calcium, the active ingredient in Crestor.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs